A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
Clinical trial NCT04209725 · TERMINATED
Trial details
- NCT number
- NCT04209725
- Sponsor
- SCRI Development Innovations, LLC
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-03
- Primary completion
- 2021-04-20
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.